DoD's $63M BinaxNow COVID-19 Ag Card Purchase from Abbott Rapid DX Raises Value Concerns

Contract Overview

Contract Amount: $63,031,864 ($63.0M)

Contractor: Abbott Rapid DX North America LLC

Awarding Agency: Department of Defense

Start Date: 2020-12-30

End Date: 2021-04-26

Contract Duration: 117 days

Daily Burn Rate: $538.7K/day

Competition Type: NOT COMPETED

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: 8507890634!BINAXNOW COVID-19 AG CARD

Place of Performance

Location: ORLANDO, ORANGE County, FLORIDA, 32810

State: Florida Government Spending

Plain-Language Summary

Department of Defense obligated $63.0 million to ABBOTT RAPID DX NORTH AMERICA LLC for work described as: 8507890634!BINAXNOW COVID-19 AG CARD Key points: 1. The contract awarded to Abbott Rapid DX North America LLC for BinaxNow COVID-19 Ag Cards represents a significant expenditure for the Defense Logistics Agency. 2. The 'NOT COMPETED' award raises questions about the potential for better pricing through a competitive bidding process. 3. The short performance period (117 days) suggests an urgent need, but the lack of competition limits transparency on price discovery. 4. The contract's value, while substantial, needs to be benchmarked against similar procurements to assess value for money. 5. The absence of small business set-aside considerations in this specific award warrants further investigation into overall DLA contracting practices. 6. The fixed-price contract type provides cost certainty but does not inherently guarantee the best possible price without competition.

Value Assessment

Rating: questionable

The awarded amount of $63,031,863.77 for BinaxNow COVID-19 Ag Cards appears high given the lack of competitive bidding. Without comparable contract data or market analysis for this specific product during the contract period, it is difficult to definitively benchmark the value. However, sole-source or limited competition awards often result in higher prices than those achieved through full and open competition. Further analysis would be needed to compare unit prices to market rates or other government agency purchases of the same or similar diagnostic tests.

Cost Per Unit: N/A

Competition Analysis

Competition Level: sole-source

This contract was awarded under a 'NOT COMPETED' status, indicating that a competitive process was not utilized. This suggests that either a waiver was granted, or the circumstances of the procurement did not allow for competition. The lack of multiple bidders means that the government did not benefit from the price discovery mechanisms inherent in a competitive environment, potentially leading to a less favorable price.

Taxpayer Impact: Taxpayers may have paid a premium for these diagnostic cards due to the absence of a competitive bidding process. The government missed an opportunity to leverage market forces to secure the most cost-effective solution.

Public Impact

The primary beneficiaries of this contract are likely military personnel and potentially other federal agencies requiring rapid COVID-19 testing capabilities. The services delivered are the provision of BinaxNow COVID-19 Ag Cards, a critical tool for disease surveillance and management. The geographic impact is primarily within the United States, supporting the Department of Defense's operational readiness and public health mission. Workforce implications are minimal in terms of direct job creation from this specific contract, but the availability of tests supports the continuity of operations for essential personnel.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Lack of competition may have led to inflated pricing.
Urgency of need might have overridden thorough market research.
Transparency in pricing is limited due to sole-source award.

Positive Signals

Contract awarded to a known entity (Abbott Rapid DX).
Fixed-price contract provides cost certainty for the government.
Product (BinaxNow) is a recognized diagnostic tool.

Sector Analysis

The procurement falls within the Healthcare and Pharmaceutical sector, specifically focusing on In-Vitro Diagnostic Substance Manufacturing. The market for COVID-19 testing supplies saw significant volatility and high demand during the pandemic. Government spending in this area was substantial across various agencies to ensure public health and operational continuity. Benchmarking this contract would ideally involve comparing unit prices with other large-scale government or commercial purchases of the same test during the same period.

Small Business Impact

This specific contract was not set aside for small businesses, nor does it appear to have explicit subcontracting requirements for small businesses mentioned in the provided data. The award to a large, established company like Abbott suggests that the focus was on rapid acquisition of a specific product rather than fostering small business participation in this instance. Further review of the Defense Logistics Agency's overall contracting strategy would be needed to assess the broader impact on the small business ecosystem.

Oversight & Accountability

Oversight for this contract would typically fall under the Defense Contract Management Agency (DCMA) and the Defense Contract Audit Agency (DCAA), ensuring compliance with contract terms and financial accountability. The Inspector General for the Department of Defense would have jurisdiction to investigate any potential fraud, waste, or abuse related to this procurement. Transparency is limited by the sole-source nature of the award, but contract modifications and payment data would be subject to review.

Related Government Programs

COVID-19 Testing Supplies Procurement
Department of Defense Medical Materiel
Defense Logistics Agency - Medical Supplies
In-Vitro Diagnostic Devices
Emergency Pandemic Response Contracts

Risk Flags

Sole-source award limits price competition.
Lack of detailed justification for non-competition.
Potential for above-market pricing.
Short contract duration may indicate urgent, potentially reactive, procurement.

Frequently Asked Questions

What is this federal contract paying for?

Department of Defense awarded $63.0 million to ABBOTT RAPID DX NORTH AMERICA LLC. 8507890634!BINAXNOW COVID-19 AG CARD

Who is the contractor on this award?

The obligated recipient is ABBOTT RAPID DX NORTH AMERICA LLC.

Which agency awarded this contract?

Awarding agency: Department of Defense (Defense Logistics Agency).

What is the total obligated amount?

The obligated amount is $63.0 million.

What is the period of performance?

Start: 2020-12-30. End: 2021-04-26.

What was the specific justification for awarding this contract on a sole-source basis?

The provided data indicates the contract was 'NOT COMPETED,' which is a strong indicator of a sole-source or limited competition award. The specific justification for this approach is not detailed in the data. Typically, sole-source awards are justified under circumstances such as urgent and compelling needs where only one responsible source can provide the supplies or services, or when a specific proprietary product is required. Without further documentation from the agency, the precise reason for bypassing full and open competition remains unclear. This lack of transparency in the justification process is a common concern with non-competitively awarded contracts.

How does the unit price of the BinaxNow COVID-19 Ag Card in this contract compare to market rates or other government purchases during the same period?

The provided data does not include the unit price, only the total award amount ($63,031,863.77) and the quantity is not specified. Therefore, a direct unit price comparison is not possible with the given information. To perform this comparison, one would need to know the exact number of test cards purchased. Subsequently, this unit price would need to be benchmarked against publicly available pricing data for the BinaxNow test from Abbott during late 2020 to early 2021, as well as against other federal contracts awarded for the same or similar rapid antigen tests during that timeframe. The lack of this comparative data makes it difficult to assess if the government secured a competitive price.

What is Abbott Rapid DX North America LLC's track record with the Department of Defense and the Defense Logistics Agency?

Abbott Rapid DX North America LLC, as a subsidiary or division of Abbott Laboratories, is a significant player in the diagnostics market. While specific contract history details are not provided in this dataset, Abbott has a well-established relationship with various government agencies, including the Department of Defense, for supplying medical and diagnostic products. Their track record would generally be assessed based on past performance, delivery timeliness, product quality, and compliance with contract terms on previous awards. A comprehensive review would involve examining their performance ratings on prior DoD contracts and any history of disputes or contract terminations.

What were the primary risks associated with this procurement, and how were they mitigated?

Key risks associated with this procurement likely included supply chain disruptions, potential for product obsolescence (as testing technology evolved), and the risk of overpaying due to the lack of competition. Given the 'NOT COMPETED' status, mitigation strategies might have focused on ensuring the supplier's capacity to meet demand, verifying the efficacy and reliability of the BinaxNow test, and potentially negotiating terms to manage price fluctuations if possible within a fixed-price structure. The short performance duration also suggests a risk of insufficient supply if demand was underestimated or if the supplier faced production issues.

How does this contract's value compare to overall DoD spending on COVID-19 related medical supplies?

The $63 million awarded for BinaxNow Ag Cards represents a fraction of the total Department of Defense spending on COVID-19 related medical supplies, which likely ran into billions of dollars across various categories including PPE, ventilators, therapeutics, and other testing modalities. This specific contract addresses a particular need for rapid antigen testing. To contextualize its value, it would need to be compared against the total budget allocated by the DoD for diagnostic testing and the proportion of that budget dedicated to antigen tests versus PCR or other molecular tests. Its significance lies in its contribution to the DoD's overall pandemic response strategy.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › In-Vitro Diagnostic Substance Manufacturing

Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP

Competition & Pricing

Extent Competed: NOT COMPETED

Solicitation Procedures: ONLY ONE SOURCE

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Parent Company: Abbott Laboratories

Address: 30 S KELLER RD STE 100, ORLANDO, FL, 32810

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $63,031,864

Exercised Options: $63,031,864

Current Obligation: $63,031,864

Contract Characteristics

Commercial Item: COMMERCIAL ITEM

Cost or Pricing Data: NO

Parent Contract

Parent Award PIID: SPE2DE20D0027

IDV Type: IDC

Timeline